Conclusion
rEg.P29166-185 can act as a dominant B-cell epitope for rEg.P29 and promote cell activation and proliferation in the same way as rEg.P29.
Methods
Immunological model was established in mice with rEg.P29. SDS-PAGE and Western blot were used to identify protein. Screening for B-cell dominant epitope peptides of rEg.P29 by enzyme-linked immunosorbent assay (ELISA) and immune serum. Dominant epitopes were validated using ELISA and flow cytometry. Multiple sequence alignment analysis was performed using BLAST and UniProt.
Results
Immunization with rEg.P29 induced intense and persistent antibody responses, and the epitope of the dominant antigen of B cells are identified as rEg.P29166-185 (LKNAKTAEQKAKWEAEVRKD). Anti-rEg.P29166-185 -specific antibodies lack epitopes against IgA, IgE, and IgG3, compared to anti-rEg.P29-specific antibodies. However, anti-rEg.P29166-185 IgG showed comparatively higher titers, as determined among those peptides by endpoint titration. In addition, rEg.P29 and rEg.P29166-185 promote B-cell activation and proliferation in vitro. The dominant epitopes are relatively conserved in different subtypes of the rEg.P29 sequence.
